Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer

被引：0

作者：

Morganti, Stefania ^{[1
,2
,3
,4
]}

Jin, Qingchun ^{[5
]}

Vincuilla, Julie ^{[2
]}

Buehler, Ryan ^{[6
]}

Ryan, Sean ^{[1
,2
]}

Stokes, Samantha ^{[4
]}

Parker, Tonia ^{[1
,2
]}

Mittendorf, Elizabeth A. ^{[2
,3
,7
]}

King, Tari A. ^{[2
,3
,7
]}

Weiss, Anna ^{[2
,3
,7
,10
]}

Partridge, Ann H. ^{[1
,2
,3
]}

Bychkovsky, Brittany L. ^{[1
,2
,3
,6
]}

Curigliano, Giuseppe ^{[8
,9
]}

Tayob, Nabihah ^{[3
,5
]}

Lin, Nancy U. ^{[1
,2
,3
]}

Garber, Judy E. ^{[1
,2
,3
,6
]}

Tolaney, Sara M. ^{[1
,2
,3
]}

Lynce, Filipa ^{[1
,2
,3
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

[2] Dana Farber Brigham Canc Ctr, Breast Oncol Program, Boston, MA 02115 USA

[3] Harvard Med Sch, Boston, MA 02115 USA

[4] Broad Inst MIT & Harvard, Boston, MA USA

[5] Dana Farber Canc Inst, Dept Data Sci, Boston, MA USA

[6] Dana Farber Canc Inst, Div Canc Genet & Prevent, Boston, MA USA

[7] Brigham & Womens Hosp, Dept Surg, Div Breast Surg, Boston, MA USA

[8] Univ Milan, Dept Oncol & Hemato Oncol, Milan, Italy

[9] European Inst Oncol IRCCS, Milan, Italy

[10] Univ Rochester, Med Ctr, Div Surg Oncol, Rochester, NY USA

来源：

NPJ BREAST CANCER | 2024年 / 10卷 / 01期

关键词：

D O I：

10.1038/s41523-024-00632-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Following the survival benefit demonstrated in the OlympiA trial, one year of adjuvant olaparib is now recommended for all patients with germline BRCA1/2 pathogenic/likely pathogenic variants (PV) and high-risk, HER2-negative early breast cancer after chemotherapy. However, optimal identification of high-risk patients who may derive benefit from this genomically-directed therapy is debated. In this study, we sought to characterize the real-world proportion of gBRCA1/2 PV carriers eligible for adjuvant olaparib according to the OlympiA criteria, and to compare clinicopathologic characteristics and outcomes between eligible and ineligible patients.

引用

页数：6

共 9 条

[1]

Center for Drug Evaluation & Research, 2022, FDA approves olaparib for adjuvant treatment of high-risk early breast cancer

[2] Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women [J].

Dorling, Leila ;

Carvalho, Sara ;

Allen, Jamie ;

Gonzalez-Neira, Anna ;

Luccarini, Craig ;

Wahlstrom, Cecilia ;

Pooley, Karen A. ;

Parsons, Michael T. ;

Fortuno, Cristina ;

Wang, Qin ;

Bolla, Manjeet K. ;

Dennis, Joe ;

Keeman, Renske ;

Alonso, M. Rosario ;

Alvarez, Nuria ;

Herraez, Belen ;

Fernandez, Victoria ;

Nunez-Torres, Rocio ;

Osorio, Ana ;

Valcich, Jeanette ;

Li, Minerva ;

Torngren, Therese ;

Harrington, Patricia A. ;

Baynes, Caroline ;

Conroy, Don M. ;

Decker, Brennan ;

Fachal, Laura ;

Mavaddat, Nasim ;

Ahearn, Thomas ;

Aittomaki, Kristiina ;

Antonenkova, Natalia N. ;

Arnold, Norbert ;

Arveux, Patrick ;

Ausems, Margreet G. E. M. ;

Auvinen, Paivi ;

Becher, Heiko ;

Beckmann, Matthias W. ;

Behrens, Sabine ;

Bermisheva, Marina ;

Bialkowska, Katarzyna ;

Blomqvist, Carl ;

Bogdanova, Natalia V. ;

Bogdanova-Markov, Nadja ;

Bojesen, Stig E. ;

Bonanni, Bernardo ;

Borresen-Dale, Anne-Lise ;

Brauch, Hiltrud ;

Bremer, Michael ;

Briceno, Ignacio ;

Bruning, Thomas .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) :428-439

[3]

EMA, 2022, Lynparza

[4] Overall survival in the OlympiA phase Ill trial of adjuvant olaparib in patients with germime pathogenic variants in BRCA1/2 and high-risk, early breast cancer [J].

Geyer, C. E., Jr. ;

Garber, J. E. ;

Gelber, R. D. ;

Yothers, G. ;

Taboada, M. ;

Ross, L. ;

Rastogi, P. ;

Cui, K. ;

Arahmani, A. ;

Aktan, G. ;

Armstrong, A. C. ;

Arnedos, M. ;

Balmana, J. ;

Bergh, J. ;

Bliss, J. ;

Delaloge, S. ;

Domchek, S. M. ;

Eisen, A. ;

Elsafy, F. ;

Fein, L. E. ;

Fielding, A. ;

Ford, J. M. ;

Friedman, S. ;

Gelmon, K. A. ;

Gianni, L. ;

Gnant, M. ;

Hollingsworth, S. J. ;

Im, S-A ;

Jager, A. ;

Lakhani, S. R. ;

Janni, W. ;

Linderholm, B. ;

Liu, T-W ;

Loman, N. ;

Korde, L. ;

Loibl, S. ;

Lucas, P. C. ;

Marme, F. ;

de Duenas, E. Martinez ;

McConnell, R. ;

Phillips, K-A ;

Piccart, M. ;

Rossi, G. ;

Schmutzler, R. ;

Senkus, E. ;

Shao, Z. ;

Sharma, P. ;

Singer, C. F. ;

Spanic, T. ;

Stickeler, E. .

ANNALS OF ONCOLOGY, 2022, 33 (12) :1250-1268

[5] A Population-Based Study of Genes Previously Implicated in Breast Cancer [J].

Hu, Chunling ;

Hart, Steven N. ;

Gnanaolivu, Rohan ;

Huang, Hongyan ;

Lee, Kun Y. ;

Na, Jie ;

Gao, Chi ;

Lilyquist, Jenna ;

Yadav, Siddhartha ;

Boddicker, Nicholas J. ;

Samara, Raed ;

Klebba, Josh ;

Ambrosone, Christine B. ;

Anton-Culver, Hoda ;

Auer, Paul ;

Bandera, Elisa V. ;

Bernstein, Leslie ;

Bertrand, Kimberly A. ;

Burnside, Elizabeth S. ;

Carter, Brian D. ;

Eliassen, Heather ;

Gapstur, Susan M. ;

Gaudet, Mia ;

Haiman, Christopher ;

Hodge, James M. ;

Hunter, David J. ;

Jacobs, Eric J. ;

John, Esther M. ;

Kooperberg, Charles ;

Kurian, Allison W. ;

Le Marchand, Loic ;

Lindstroem, Sara ;

Lindstrom, Tricia ;

Ma, Huiyan ;

Neuhausen, Susan ;

Newcomb, Polly A. ;

O'Brien, Katie M. ;

Olson, Janet E. ;

Ong, Irene M. ;

Pal, Tuya ;

Palmer, Julie R. ;

Patel, Alpa V. ;

Reid, Sonya ;

Rosenberg, Lynn ;

Sandler, Dale P. ;

Scott, Christopher ;

Tamimi, Rulla ;

Taylor, Jack A. ;

Trentham-Dietz, Amy ;

Vachon, Celine M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) :440-451

[6] Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial [J].

Johnston, Stephen R. D. ;

Toi, Masakazu ;

O'Shaughnessy, Joyce ;

Rastogi, Priya ;

Campone, Mario ;

Neven, Patrick ;

Huang, Chiun-Sheng ;

Huober, Jens ;

Jaliffe, Georgina Garnica ;

Cicin, Irfan ;

Tolaney, Sara M. ;

Goetz, Matthew P. ;

Rugo, Hope S. ;

Senkus, Elzbieta ;

Testa, Laura ;

Del Mastro, Lucia ;

Shimizu, Chikako ;

Wei, Ran ;

Shahir, Ashwin ;

Munoz, Maria ;

San Antonio, Belen ;

Andre, Valerie ;

Harbeck, Nadia ;

Martin, Miguel .

LANCET ONCOLOGY, 2023, 24 (01) :77-90

[7] Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies [J].

Morganti, Stefania ;

Bychkovsky, Brittany L. ;

Poorvu, Philip D. ;

Garrido-Castro, Ana C. ;

Weiss, Anna ;

Block, Caroline C. ;

Partridge, Ann H. ;

Curigliano, Giuseppe ;

Tung, Nadine M. ;

Lin, Nancy U. ;

Garber, Judy E. ;

Tolaney, Sara M. ;

Lynce, Filipa .

ONCOLOGIST, 2023, 28 (07) :565-574

[8] Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0 [J].

Tolaney, Sara M. ;

Garrett-Mayer, Elizabeth ;

White, Julia ;

Blinder, Victoria S. ;

Foster, Jared C. ;

Amiri-Kordestani, Laleh ;

Hwang, E. Shelley ;

Bliss, Judith M. ;

Rakovitch, Eileen ;

Perlmutter, Jane ;

Spears, Patricia A. ;

Frank, Elizabeth ;

Tung, Nadine M. ;

Elias, Anthony D. ;

Cameron, David ;

Denduluri, Neelima ;

Best, Ana F. ;

DiLeo, Angelo ;

Baizer, Lawrence ;

Butler, Lynn Pearson ;

Schwartz, Elena ;

Winer, Eric P. ;

Korde, Larissa A. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (24) :2720-+

[9] Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer [J].

Tutt, Andrew N. J. ;

Garber, Judy E. ;

Kaufman, Bella ;

Viale, Giuseppe ;

Fumagalli, Debora ;

Rastogi, Priya ;

Gelber, Richard D. ;

de Azambuja, Evandro ;

Fielding, Anitra ;

Balmana, Judith ;

Domchek, Susan M. ;

Gelmon, Karen A. ;

Hollingsworth, Simon J. ;

Korde, Larissa A. ;

Linderholm, Barbro ;

Bandos, Hanna ;

Senkus, E. ;

Suga, Jennifer M. ;

Shao, Z. ;

Pippas, Andrew W. ;

Nowecki, Zbigniew ;

Huzarski, Tomasz ;

Ganz, Patricia A. ;

Lucas, Peter C. ;

Baker, Nigel ;

Loibl, Sibylle ;

McConnell, Robin ;

Piccart, Martine ;

Schmutzler, Rita ;

Steger, Guenther G. ;

Costantino, Joseph P. ;

Arahmani, Amal ;

Wolmark, Norman ;

McFadden, Eleanor ;

Karantza, Vassiliki ;

Lakhani, Sunil R. ;

Yothers, Greg ;

Campbell, Christine ;

Geyer, Charles E. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (25) :2394-2405

← 1 →